Which Penny Stocks Are About to Explode? 7 High-Upside Picks to Watch in 2026

Every trader asks the same question at some point: which penny stocks are about to explode? It’s the kind of question that keeps you glued to your screen, refreshing prices, scrolling through news, and second-guessing every move. And honestly, it’s the right question to ask—because when a sub-$5 stock catches fire, the moves can be dramatic. But knowing which ones have real fuel behind them versus just speculative noise is where the real challenge lies.

So let’s cut through the noise. Here’s a look at seven penny stocks with genuine catalysts, analyst backing, and the kind of momentum that makes traders sit up and pay attention.

Gold Royalty Corp (GROY)

Gold Royalty has been on a tear, with the stock gaining over 140% in the past year, and analysts see it climbing another 60% in the next 12 months . The company offers financing to mining operations in exchange for royalties and streaming interests, which means investors get exposure to gold, silver, and copper without the operational headaches of running a mine . In Q1 2026, revenue hit a record $7.2 million—up from $3.1 million a year ago—and the company swung from a net loss to a $1.8 million profit . With no debt and over $13.6 million in cash, GROY has the balance sheet to weather volatility.

Antelope Enterprise Holdings (AEHL)

AEHL operates a livestream e-commerce business in China and is expanding into U.S. power generation for data centers and AI infrastructure. On August 31 alone, the stock rallied 83.3%, with a dollar volume of over $306 million . The jump came after the company announced an $18.99 million private placement, bringing in fresh funding for its AI-related expansion. High risk? Absolutely. But the kind of volume and price action that makes traders pay attention.

Opus Genetics (IRD)

This is one of those overlooked penny stocks that analysts are quietly bullish on. RBC Capital initiated coverage in June with an "Outperform" rating and a $10 price target, citing limited competition, de-risked science, and recent FDA leniency . The company is developing gene therapies for inherited retinal diseases, with key data readouts expected in September 2026 and more in 2027 . Shares are up nearly 110% year-to-date, and if the data hits, this could be one of those breakout stories.

Exagen Inc. (XGN)

Over 80% of analysts covering Exagen maintain a "Buy" rating, with a consensus price target implying 235% upside . The diagnostics company focuses on autoimmune disease testing and reported 20% year-over-year revenue growth in its latest earnings. Craig-Hallum recently trimmed its price target to $10 from $12 but maintained a Buy rating, noting that test volume is accelerating as planned . If margins improve, the upside could be substantial.

bioAffinity Technologies (BIAF)

BIAF surged 19.5% on September 4 with a dollar volume exceeding $306 million . The company uses flow cytometry and AI for non-invasive lung cancer detection—a space with massive unmet need. Its lead product, CyPath Lung, helps doctors determine whether new nodules detected on CT scans are likely malignant, potentially saving patients from unnecessary invasive procedures .

Ur-Energy (URG)

This uranium miner is riding the global nuclear revival. With the International Atomic Energy Agency projecting global nuclear capacity could double by 2050, Ur-Energy is positioned as a low-cost producer with its flagship Lost Creek project in Wyoming and the Shirley Basin project expected to boost production later this year . Analysts have a consensus price target of $2.57, suggesting meaningful upside from current levels .

Western Copper and Gold (WRN)

WRN has soared around 180% over the past year and is forecast to explode more than 80% over the next 12 months . The company strengthened its balance sheet in Q1, exiting with C$134.4 million in cash after a C$92 million equity financing . Its flagship Casino project in Yukon is in the permitting stage—a potential company-maker if approvals come through.

---

Now here’s the thing. When you’re tracking stocks like these—multiple positions, real-time moves, volatility that can spike in minutes—your attention is split. You can’t sit there with MT5 or MT4 open all day, staring at charts while pretending to do other things. But you also can’t afford to miss a price alert or a position that suddenly goes against you.

That’s where something like Camovia Tray comes into play. It turns your MT5 or MT4 into a tray tool—so you can check live quotes, view open positions, and even close trades with a click, all from the system tray. No need to have the full terminal window open on your screen. Hover over the tray icon, see your watchlist prices, manage your positions, and get back to whatever else you’re doing. It keeps your data local, supports both MT5 and MT4, and even lets you hide the main window entirely if you need to keep things low-profile.

Because when a penny stock starts moving, you don’t want to be fumbling around trying to bring up a terminal window. You want to see the price and act—fast.